PERJETA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States

Active ingredients

The drug PERJETA contains one active pharmaceutical ingredient (API):

1 Pertuzumab UNII K16AIQ8CTM - PERTUZUMAB

Pertuzumab is a recombinant humanised monoclonal antibody that specifically targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab inhibits ligand-initiated intracellular signalling through two major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively. Read about Pertuzumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PERJETA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FD02	Pertuzumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
Discover more medicines within L01FD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10267J, 10308M, 10333W, 10334X
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 529213110025202
Country: CA	Health Products and Food Branch	Identifier(s): 02405016
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): H3120113
Country: EE	Ravimiamet	Identifier(s): 1609512
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 113813001, 113813001IP
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 574423
Country: FR	Base de données publique des médicaments	Identifier(s): 60912227
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 221354, 368194
Country: HK	Department of Health Drug Office	Identifier(s): 62758
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7116
Country: IT	Agenzia del Farmaco	Identifier(s): 042682017, 050953013
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291424A1020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1069701
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 105422
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 15722
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100299600
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64394001
Country: SG	Health Sciences Authority	Identifier(s): 14501P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 6993211H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699505762791
Country: US	FDA, National Drug Code	Identifier(s): 50242-145